The treatment of epilepsy in pregnancy: The neurodevelopmental risks associated with exposure to antiepileptic drugs

Reproductive Toxicology

Volumn 64, Issue , 2016, Pages 203-210

  Bromley, R ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Anti epileptic drugs; Epilepsy; Neurodevelopment; Pregnancy; Teratology

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ARTICLE; CHILD HEALTH; DISEASE ASSOCIATION; DISEASE SEVERITY; EPILEPSY; FETUS RISK; HIGH RISK PREGNANCY; HUMAN; INTELLIGENCE QUOTIENT; MATERNAL TREATMENT; MATERNAL WELFARE; META ANALYSIS (TOPIC); NERVE CELL DIFFERENTIATION; NEURODEVELOPMENTAL RISK; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; RISK; TERATOLOGY; CHEMICALLY INDUCED; CHILD; DRUG EFFECTS; DRUG INDUCED MALFORMATION; EMBRYOLOGY; FEMALE; NERVOUS SYSTEM; PATHOPHYSIOLOGY;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CHILD; EPILEPSY; FEMALE; HUMANS; NERVOUS SYSTEM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK;

EID: 84992469980     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2016.06.007     Document Type: Article

References (93)

1. [1] Holmes, L.B., Harvey, E.A., Coull, B.A., Huntington, K.B., Khoshbin, S., Hayes, A.M., et al. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med. 344:15 (2001), 1132–1138.
2. [2] Wen, X., Meador, K.J., Hartzema, A., Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. Neurology 84:9 (2015), 944–950.
3. [3] Man, S.L., Petersen, I., Thompson, M., Nazareth, I., Antiepileptic drugs during pregnancy in primary care: a UK population based study. PLoS One, 7(12), 2012, e52339.
4. [4] Artama, M., Auvinen, A., Raudaskoski, T., Isojarvi, I., Isojarvi, J., Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64:11 (2005), 1874–1878.
5. [5] Ackers, R., Besag, F.M., Wade, A., Murray, M.L., Wong, I.C., Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch. Dis. Child. 94:6 (2009), 443–447.
6. [6] Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Sabers, A., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 10:7 (2011), 609–617.
7. [7] Lindhout, D., Schmidt, D., In-utero exposure to valproate and neural tube defects. Lancet 327:8494 (1986), 1392–1393.
8. [8] Samren, E.B., Van Duijn, C.M., Christiaens, G.C., Hofman, A., Lindhout, D., Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 46:5 (1999), 739–746.
9. [9] Jentink, J., Loane, M.A., Dolk, H., Barisic, I., Garne, E., Morris, J.K., et al. Valproic acid monotherapy in pregnancy and major congenital malformations. New Engl. J. Med. 362:23 (2010), 2185–2193.
10. [10] Diav-Citrin, O., Shechtman, S., Bar-Oz, B., Cantrell, D., Arnon, J., Ornoy, A., Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs 22:4 (2008), 325–334.
11. [11] Jager-Roman, E., Deichl, A., Jakob, S., Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J. Pediatr. 108:6 (1986), 997–1004.
12. [12] Jackson, A., Bromley, R., Morrow, J., Irwin, B., Clayton-Smith, J., In utero exposure to valproate increases the risk of isolated cleft palate. Arch. Dis. Child. Fetal Neonatal Ed. 101:3 (2016), pF207–211.
13. [13] Lindhout, D., Meinardi, H., Meijer, J.W., Nau, H., Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 42:Suppl. 5 (1992), 94–110.
14. [14] Jentink, J., Dolk, H., Loane, M.A., Morris, J.K., Wellesley, D., Garne, E., et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ, 341, 2010, c6581.
15. [15] Kaneko, S., Otani, K., Fukushima, Y., Ogawa, Y., Nomura, Y., Ono, T., et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29:4 (1988), 459–467.
16. [16] Hernandez-Diaz, S., Smith, C.R., Shen, A., Mittendorf, R., Hauser, W.A., Yerby, M., et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 78:21 (2012), 1692–1699.
17. [17] Kallen, B., Robert, E., Mastroiacovo, P., Martinez-Frias, M.L., Castilla, E.E., Cocchi, G., Anticonvulsant drugs and malformations is there a drug specificity?. Eur. J. Epidemiol. 5:1 (1989), 31–36.
18. [18] Meador, K., Reynolds, M.W., Crean, S., Fahrbach, K., Probst, C., Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 81:1 (2008), 1–13.
19. [19] Campbell, E., Kennedy, F., Russell, A., Smithson, W.H., Parsons, L., Morrison, P.J., et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J. Neurol. Neurosurg. Psychiatry 85:9 (2014), 1029–1034.
20. [20] Vajda, F.J., O'Brien, T.J., Lander, C.M., Graham, J., Eadie, M.J., The teratogenicity of the newer antiepileptic drugs − an update. Acta Neurol. Scand. 130:4 (2014), 234–238.
21. [21] Molgaard-Nielsen, D., Hviid, A., Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305:19 (2011), 1996–2002.
22. [22] Cunnington, M., Tennis, P., Lamotrigine and the risk of malformations in pregnancy. Neurology 64:6 (2005), 955–960.
23. [23] Holmes, L.B., Baldwin, E.J., Smith, C.R., Habecker, E., Glassman, L., Wong, S.L., et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70:22 (2008), 2152–2158.
24. [24] Mawhinney, E., Craig, J., Morrow, J., Russell, A., Smithson, W.H., Parsons, L., et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 80:4 (2013), 400–405.
25. [25] Tennis, P., Chan, K.A., Curkendall, S.M., Li, D.K., Mines, D., Peterson, C., et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res. A Clin. Mol. Teratol. 103:4 (2015), 269–275.
26. [26] Alsaad, A.M., Chaudhry, S.A., Koren, G., First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reprod. Toxicol. 53 (2015), 45–50.
27. [27] Fujii, H., Goel, A., Bernard, N., Pistelli, A., Yates, L.M., Stephens, S., et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 80:17 (2013), 1565–1570.
28. [28] Winter, R.M., Donnai, D., Burn, J., Tucker, S.M., Fetal valproate syndrome: is there a recognisable phenotype?. J. Med. Genet. 24:11 (1987), 692–695.
29. [29] Clay, S.A., McVie, R., Chen, H., Possible teratogenic effect of valproic acid. J. Pediatr., 99(5), 1981, 828.
30. [30] Kogutt, M.S., Fetal hydantoin syndrome. South. Med. J. 77:5 (1984), 657–658.
31. [31] Krauss, C.M., Holmes, L.B., VanLang, Q.C., Keith, D.A., Four siblings with similar malformations after exposure to phenytoin and primidone. J. Pediatr. 105:5 (1984), 750–755.
32. [32] Massa, G., Lecoutere, D., Casaer, P., Prognosis in fetal valproate syndrome. J. Pediatr. 111:2 (1987), 308–310.
33. [33] Meador, K.J., Baker, G.A., Browning, N., Clayton-Smith, J., Combs-Cantrell, D.T., Cohen, M., et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360:16 (2009), 1597–1605.
34. [34] Bromley, R.L., Mawer, G., Love, J., Kelly, J., Purdy, L., McEwan, L., et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 51:10 (2010), 2058–2065.
35. [35] Gaily, E., Kantola-Sorsa, E., Hiilesmaa, V., Isoaho, M., Matila, R., Kotila, M., et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62:1 (2004), 28–32.
36. [36] Wide, K., Henning, E., Tomson, T., Winbladh, B., Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr. 91:4 (2002), 409–414.
37. [37] Wide, K., Winbladh, B., Tomson, T., Sars-Zimmer, K., Berggren, E., Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: a prospective population-based study. Dev. Med. Child Neurol. 42:2 (2000), 87–92.
38. [38] Nadebaum, C., Anderson, V., Vajda, F., Reutens, D., Barton, S., Wood, A., The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J. Int. Neuropsychol. Soc. 17:1 (2011), 133–142.
39. [39] Thomas, S.V., Ajaykumar, B., Sindhu, K., Nair, M.K.C., George, B., Sarma, P.S., Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 13:1 (2008), 229–236.
40. [40] Cummings, C., Stewart, M., Stevenson, M., Morrow, J., Nelson, J., Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch. Dis. Child. 96:7 (2011), 643–647.
41. [41] Shallcross, R., Bromley, R.L., Irwin, B., Bonnett, L.J., Morrow, J., Baker, G.A., et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 76:4 (2011), 383–389.
42. [42] Deshmukh, U., Adams, J., Macklin, E.A., Dhillon, R., McCarthy, K.D., Dworetzky, B., et al. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol. Teratol. 54 (2016), 5–14.
43. [43] Bayley, N., Bayley Scales of Infant and Toddler Development. 2006, Pearson Inc.
44. [44] Leavitt, A.M., Yerby, M.S., Robinson, N., Sells, C.J., Erickson, D.M., Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 199242:Suppl. 5 (2016), 141–143.
45. [45] Bromley, R., Weston, J., Adab, N., Greenhalgh, J., Sanniti, A., McKay, A.J., et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst. Rev., 10, 2014, Cd010236.
46. [46] Baker, G.A., Bromley, R.L., Briggs, M., Cheyne, C.P., Cohen, M.J., Garcia-Finana, M., et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84:4 (2015), 382–390.
47. [47] Adab, N., Kini, U., Vinten, J., Ayres, J., Baker, G., Clayton-Smith, J., et al. The longer term outcome of children born to mothers with epilepsy Journal of Neurology. Neurosurg. Psychiatry 75:11 (2004), 1575–1583.
48. [48] Meador, K.J., Baker, G.A., Browning, N., Cohen, M.J., Bromley, R.L., Clayton-Smith, J., et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 12:3 (2013), 244–252.
49. [49] Baker, G.A., Bromley, R.L., Briggs, M., Cheyne, C.P., Cohen, M.J., Garcia-Finana, M., et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84:4 (2015), 382–390.
50. [50] Rovet, J., Cole, S., Nulman, I., Scolnik, D., Altmann, D., Koren, G., Effects of maternal epilepsy on children's neurodevelopment. Child Neuropsychol. 1:2 (1995), 150–157.
51. [51] Veiby, G., Daltveit, A.K., Schjolberg, S., Stoltenberg, C., Oyen, A.S., Vollset, S.E., et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia 54:8 (2013), 1462–1472.
52. [52] Nadebaum, C., Anderson, V.A., Vajda, F., Reutens, D.C., Barton, S., Wood, A.G., Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 76:8 (2011), 719–726.
53. [53] Ornoy, A., Cohen, E., Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch. Dis. Child. 75:6 (1996), 517–520.
54. [54] Arulmozhi, T., Dhanaraj, M., Rangaraj, R., Vengatesan, A., Physical growth and psychomotor development of infants exposed to antiepileptic drugs in utero. Neurol. India 54:1 (2006), 42–46.
55. [55] Cohen, M.J., Meador, K.J., Browning, N., Baker, G.A., Clayton-Smith, J., Kalayjian, L.A., et al. Fetal antiepileptic drug exposure: motor, adaptive and emotional/behavioral functioning at age 3years. Epilepsy Behav. 22:2 (2011), 240–246.
56. [56] Rihtman, T., Parush, S., Ornoy, A., Developmental outcomes at preschool age after fetal exposure to valproic acid and lamotrigine: cognitive, motor, sensory and behavioral function. Reprod. Toxicol. 41 (2013), 115–125.
57. [57] Shallcross, R., Bromley, R.L., Cheyne, C.P., Garcia-Finana, M., Irwin, B., Morrow, J., et al. In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. Neurology 82:3 (2014), 213–221.
58. [58] Speidel, B.D., Meadow, S.R., Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 2:7782 (1972), 839–843.
59. [59] Thomas, S.V., Sukumaran, S., Lukose, N., George, A., Sarma, P., Intellectual and language functions in children of mothers with epilepsy. Epilepsia 48:12 (2007), 2234–2240.
60. [60] van der Pol, M.C., Hadders-Algra, M., Huisjes, H.J., Touwen, B.C., Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am. J. Obstet. Gynecol. 164:1 Pt 1 (1991), 121–128.
61. [61] Dean, J.C.S., Hailey, H., Moore, S.J., Lloyd, D.J., Turnpenny, P.D., Little, J., Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J. Med. Genet. 39:4 (2002), 251–259.
62. [62] Dessens, A.B., Cohen-Kettenis, P.T., Mellenbergh, G.J., Koppe, J.G., van De Poll, N.E., Boer, K., Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems. Acta Paediatr. 89:5 (2000), 533–541.
63. [63] D'Souza, S.W., Robertson, I.G., Donnai, D., Mawer, G., Fetal phenytoin exposure, hypoplastic nails and jitteriness. Arch. Dis. Child. 66:3 (1991), 320–324.
64. [64] Rihtman, T., Parush, S., Ornoy, A., Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod. Toxicol. 34:3 (2012), 308–311.
65. [65] Kantola-Sorsa, E., Gaily, E., Isoaho, M., Korkman, M., Neuropsychological outcomes in children of mothers with epilepsy. J. Int. Neuropsychol. Soc. 13:4 (2007), 642–652.
66. [66] Vinten, J., Adab, N., Kini, U., Gorry, J., Gregg, J., Baker, G.A., Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64:6 (2005), 949–954.
67. [67] Adab, N., Jacoby, A., Smith, D., Chadwick, D., Additional educational needs in children born to mothers with epilepsy. J. Neurol. Neurosurg. Psychiatry 70:1 (2001), 15–21.
68. [68] Williams, G., King, J., Cunningham, M., Stephan, M., Kerr, B., Hersh, J.H., Fetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child Neurol. 43:3 (2001), 202–206.
69. [69] Bescoby-Chambers, N., Forster, P., Bates, G., Foetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child Neurol., 43(12), 2001, 847.
70. [70] Rasalam, A.D., Hailey, H., Williams, J.H., Moore, S.J., Turnpenny, P.D., Lloyd, D.J., et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev. Med. Child Neurol. 47:8 (2005), 551–555.
71. [71] Bromley, R., Mawer, G., Clayton-Smith, J., Baker, G., Autism spectrum disorders following in untero exposure to antiepileptic drugs. Neurology 71:23 (2008), 1923–1924.
72. [72] Bromley, R.L., Mawer, G.E., Briggs, M., Cheyne, C., Clayton-Smith, J., Garcia-Finana, M., et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J. Neurol. Neurosurg. Psychiatry 84:6 (2013), 637–643.
73. [73] Wood, A.G., Nadebaum, C., Anderson, V., Reutens, D., Barton, S., O'Brien, T.J., et al. Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia 56:7 (2015), 1047–1055.
74. [74] Christensen, J., Gronborg, T.K., Sorensen, M.J., Schendel, D., Parner, E.T., Pedersen, L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309:16 (2013), 1696–1703.
75. [75] Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368:9531 (2006), 210–215.
76. [76] Holmes, L.B., Rosenberger, P.B., Harvey, E.A., Khoshbin, S., Ryan, L., Intelligence and physical features of children of women with epilepsy. Teratology 61:3 (2000), 196–202.
77. [77] Bromfield, E.B., Dworetzky, B.A., Wyszynski, D.F., Smith, C.R., Baldwin, E.J., Holmes, L.B., Valproate teratogenicity and epilepsy syndrome. Epilepsia 49:12 (2008), 2122–2124.
78. [78] King, P.B., Lie, R.T., Irgens, L.M., Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. Am. J. Public Health 86:10 (1996), 1454–1456.
79. [79] Fried, S., Kozer, E., Nulman, I., Einarson, T.R., Koren, G., Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf. 27:3 (2004), 197–202.
80. [80] Cassina, M., Dilaghi, A., Di Gianantonio, E., Cesari, E., De Santis, M., Mannaioni, G., et al. Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reprod. Toxicol. 39 (2013), 50–57.
81. [81] Arndt, T.L., Stodgell, C.J., Rodier, P.M., The teratology of autism. Int. J. Dev. Neurosci. 23:2–3 (2005), 189–199.
82. [82] Ingram, J.L., Peckham, S.M., Tisdale, B., Rodier, P.M., Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22:3 (2000), 319–324.
83. [83] Shapiro, S., Hartz, S.C., Siskind, V., Mitchell, A.A., Slone, D., Rosenberg, L., et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1:7954 (1976), 272–275.
84. [84] Bjørk, M.H., Veiby, G., Spigset, O., Gilhus, N.E., Using the Norwegian Mother and Child Cohort Study to determine risk factors for delayed development and neuro-psychiatric symptoms in the offspring of parents with epilepsy. Norsk Epidemiol. 24:1–2 (2014), 79–89.
85. [85] Marson, A.G., Al-Kharusi, A.M., Alwaidh, M., Appleton, R., Baker, G.A., Chadwick, D.W., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369:9566 (2007), 1016–1026.
86. [86] Tomson, T., Marson, A., Boon, P., Canevini, M.P., Covanis, A., Gaily, E., et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 56:7 (2015), 1006–1019.
87. [87] European Medicines Agency Valproate and related substances. Assessment Report. Procedure Under Article 31 of Directive 2001/83/EC. Resulting from Pharmacovigilance Data. 2014 [15/03/2016]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substances/human_referral_prac_000032.jsp&mid=WC0b01ac05805c516f.
88. [88] Gaily, E., Kantola-Sorsa, E., Granstrom, M.L., Intelligence of children of epileptic mothers. J. Pediatr. 113:4 (1988), 677–684.
89. [89] Chevallier, B.N.V., Bidat, E., Lagardere, B., Fetal valproate syndrome and somatic and psychomotor development. Arch. French Pediatr. 46 (1989), 627–628.
90. [90] Deary, I.J., Strand, S., Smith, P., Fernandes, C., Intelligence and educational achievement. Intelligence 35:1 (2007), 13–21.
91. [91] Waller, J.H., Achievement and social mobility: relationships among IQ score, education, and occupation in two generations. Soc. Biol. 18:3 (1971), 252–259.
92. [92] Wraw, C., Deary, I.J., Gale, C.R., Der, G., Intelligence in youth and health at age 50. Intelligence 53 (2015), 23–32.
93. [93] Scolnik, D., Nulman, I., Rovet, J., Gladstone, D., Czuchta, D., Gardner, H.A., et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 271:10 (1994), 767–770.